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Background: Mining novel breast cancer genes is an important task in breast cancer research. Many approaches
prioritize candidate genes based on their similarity to known cancer genes, usually by integrating multiple data
sources. However, different types of data often contain varying degrees of noise. For effective data integration, it’s
important to design methods that work robustly with respect to noise.
Results: Gene Ontology (GO) annotations were often utilized in cancer gene mining works. However, the vast majority
of GO annotations were computationally derived, thus not completely accurate. A set of genes annotated with breast
cancer enriched GO terms was adopted here as a set of source data with realistic noise. A novel noise tolerant approach
was proposed to rank candidate breast cancer genes using noisy source data within the framework of a comprehensive
human Protein-Protein Interaction (PPI) network. Performance of the proposed method was quantitatively evaluated by
comparing it with the more established random walk approach. Results showed that the proposed method exhibited
better performance in ranking known breast cancer genes and higher robustness against data noise than the random
walk approach. When noise started to increase, the proposed method was able to maintained relatively stable
performance, while the random walk approach showed drastic performance decline; when noise increased to a large
extent, the proposed method was still able to achieve better performance than random walk did.
Conclusions: A novel noise tolerant method was proposed to mine breast cancer genes. Compared to the well
established random walk approach, it showed better performance in correctly ranking cancer genes and worked
robustly with respect to noise within source data. To the best of our knowledge, it’s the first such effort to
quantitatively analyze noise tolerance between different breast cancer gene mining methods. The sorted gene list can
be valuable for breast cancer research. The proposed quantitative noise analysis method may also prove useful for
other data integration efforts. It is hoped that the current work can lead to more discussions about influence of data
noise on different computational methods for mining disease genes.
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Novel disease genes remain difficult to identify in most
genetic diseases, and in particular, in highly polygenic
disorders. Currently, not all genes have yet been detected
even for those diseases whose molecular mechanisms
are partially known [1], for instance, breast cancer [2].
Breast cancer is a common cancer and a major cause of
cancer death among females around the world, which
makes up 23% of total cancer cases and 14% of cancer
deaths [3]. Mining breast cancer genes is conducive to
understand its pathogenic mechanism and search for* Correspondence: jkyu@home.ipe.ac.cn
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reproduction in any medium, provided the oreffective treatments. With rapid growth of disease-related
genomic and functional data, computational approaches
can be utilized to mine for new cancer genes [4].
In the past two decades, a number of computational
methods had been developed to mine potential disease
related genes. Most of those methods rank candidate
genes based on the idea that proteins similar to each other
tend to cause similar or same diseases [5]. They involve
setting up a candidate gene set to be compared with a
known disease gene set on their physical or functional
attributes [6]. On one hand, physical attribute-based
methods include screening direct neighbors of known
disease genes in the PPI network [7,8], comparing shortest
path length [9] between candidate genes and knowntd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease modules in the interaction network [10-12]. Some
approaches also used global network features to find genes
similar with known disease genes [13,14]. On the other
hand, several methods rely on functional similarities
between candidate and disease genes [15], for example,
some methods measured similarity between genes by
their functional annotations [16] (e.g., Gene Ontology
(GO) [17]). Methods using other data sources had also
been developed, such as gene expression [18,19], biological
pathways and sequence features [20].
Cancers such as breast cancer are complex and hetero-
geneous in nature, cancer-related genes often do not
function in isolation but interact with one another [5].
Integrating multiple data types was found to be effective for
gene mining in alleviating problems caused by incomplete
information [21-23]. For instance, ENDEAVOUR [24] is
an online tool based on using multiple data sources. It
integrated candidate gene rankings from different data
sources into a final ranking with the order statistic algo-
rithm. However, different data categories usually contain
inherent noise or systematic errors [25]. For instance, data
from computational predictions will no doubt contain
some amount of uncertainty. Experimental data obtained
from different labs or experimental platforms can contain
appreciable amount of noise. Noise in source data can
push computed results away from their true values, lead
to erroneous reporting.
A better method must be able to tolerate certain
amount of noise, which makes the integration of different
data sources more applicable to real-life scenarios. Despite
the fact that some approaches can work with precision
when presented with highly accurate data, few studies
have shown that those methods worked robustly when
faced with increasingly noisy data. A number of papers
had discussed the task of balancing noise and precision
when using multiple data sources for cancer gene mining,
however, hardly anyone had analyzed the noise problem
quantitatively [26-29]. It is important to calibrate how
robust a method works with respect to noise, namely, how
fast a method deteriorates when percentage of noise in
source data goes up. With that knowledge, users can then
be confident about the method’s effectiveness when it is
applied to real life data sets.
To tackle the data noise problem, a novel noise tolerant
data fusion approach was proposed here for breast cancer
gene mining (Figure 1), which integrated information
from PPI network with gene expression data to rank genes
based on their probabilities of being breast cancer related.
Satisfactory results were obtained even when noise level
was high. To demonstrate advantages of the proposed
method, its performance was compared with that of the
random walk method [13], which utilized a node’s global
neighborhood in a network to rank genes. Random walkbased methods had been shown to produce good perform-
ance [18,23,29-31] in gene ranking. Results showed the
proposed method exhibited better robustness when faced
with increasingly noisy data, as compared to the random
walk approach.Results and discussion
An effective data integration method was developed to
mine breast cancer genes from four major data sources:
Protein-Protein interactions, gene expression data, GO
annotations, and known breast cancer genes (Table 1).
After removing redundancy, a comprehensive human
PPI network was constructed with data obtained from
multiple interactions databases. The resultant network
contained a total of 156,459 PPIs with 15,494 genes. A
noise tolerant method was designed to rank potential
breast cancer genes.Rationale for data integration
A network-based score (SN) and an expression-based
score (SE) were respectively derived for each gene, which
were then integrated into a final score (S) by weighting
them with a coefficient λ. A P-score was computed to
represent performance of the proposed method when λ
was changed from 0 to 1. P-score was the average ranking
of known breast cancer genes in top 10% of the final
gene ranking list (see Methods). Smaller P-score (ranked
higher) meant better performance (Figure 2). As shown
in Figure 2, better performance was achieved when λ=0
(i.e., using only network-based ranking) compared
with λ=1 (i.e., using only expression-based ranking); the
best performance was obtained when λ=0.2, which sug-
gested that utilizing genes’ complex relations in the
PPI network can help cancer gene mining tasks. It also
confirmed that multiple data sources can complement
each other in ranking cancer genes. Final ranking results
were listed in Additional file 1: Table S1.Evaluation of performance in ranking known cancer genes
Known cancer genes were derived from the OMIM (Online
Mendelian Inheritance in Man) and CGC (Cancer Gene
Census) databases (see Methods). Known breast cancer
genes derived from OMIM was called OMIMSet, those
from CGC called CGCSet. OMIMSet was used to train the
proposed method, and CGCSet was used for evaluation.
Table 2 showed that the proposed method achieved better
performance in ranking known breast cancer genes.
Counting only genes ranked in top 10%, the proposed
method achieved an average ranking of 279, compared with
545 by random walk. Counting all 11 genes in CGCSet, the
proposed method achieved an average ranking of 1801,
compared with 2207 by random walk.
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Figure 1 Schematic chart for mining breast cancer genes. Four different types of data were used as input: PPI data, human gene expression
data, known breast cancer genes and GO annotations. Gene expression data (GDSes) from the GEO database were clustered. Known breast
cancer genes and their enriched GO annotations were used to rank genes in those clusters. From the PPI network, three network topological
attributes were computed to rank genes in the network. Finally, all individual rankings were combined into a final rank, which represents a gene’s
overall probability of being involved in breast cancer.
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In general, a method based on multiple types of know-
ledge is more objective than those utilizing singular infor-
mation; combining independent data sources can alleviate
effects of biases inherent in single data types [32]. Most
data sets, especially genome wide data, tend to contain
appreciable amount of noise. For instance, GO is a powerful
tool which provides a controlled vocabulary to describe
biological functions on multiple levels [33]. It was also
widely used on cancer research (there are about 39,000
citations for GO in Google Scholar by Oct. 16, 2012).
However, not all GO annotations are equally credible
[34]. As of October 2012, there were over 3 million GO
annotations for Homo sapiens genes. Each GO annotationincludes an evidence code to indicate how the annotation
was inferred. All evidence codes (except IEA, which
is automatically derived) are manually assigned. They
can be divided into four categories: experimental
(EXP, IDA, IPI, IMP, IGI, and IEP), computational
analysis (ISS, ISO, ISA, ISM, IGC, IBA, IBD, IKR,
IRD, and RCA), author statements (TAS and NAS),
and curatorial statements (IC and ND). For Homo sa-
piens, 16 evidence codes were used to describe GO
annotations [35]. The vast majority of GO annota-
tions were found to be computationally derived and
not manually curated (IEA evidence code) (Figure 3).
GO annotations therefore contain appreciable amount
of noise within themselves.
Table 1 Data source
Data categories Volume of input data Original sources/tools Volume of original data Download date
PPI network 156,459 PPIs HPRD 39,240 PPIs Mar. 3, 2013
BioGRID 129,180 PPIs Mar. 3, 2013
homoMINT 33,502 PPIs Mar. 3, 2013
IntAct 95,746 PPIs Mar. 3, 2013
Human Signalling Network 59,111 PPIs Mar. 3, 2013
Gene expression data 53 GDSes GEO 57 GDSes Apr. 7, 2011
Known cancer genes 37 genes OMIM 30 genes Mar. 3, 2013
CGC 19 genes Mar. 3, 2013
GO term (BP) 80 terms DAVID* 50 terms Mar. 3, 2013
GOEAST* 50 terms Mar. 3, 2013
GOstats* 50 terms Mar. 3, 2013
Cancer-hallmark GO terms 9 terms Mar. 3, 2013
* For the known breast cancer gene set, three tools were used to perform the enrichment analyses of GO terms in the BP sub-ontology: DAVID (http://david.abcc.
ncifcrf.gov/home.jsp), GOEAST (http://omicslab.genetics.ac.cn/GOEAST/), and GOstats (R package in Bioconductor). DAVID and GOEAST are web tools; GOstats is an
R package from Bioconductor. Cancer-hallmark GO terms were extracted from Table 1 of [37].
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to noise are needed if they are to prove useful in cancer
gene hunting endeavours. Nevertheless, as mentioned
before, few projects had specifically analysed data noise
effects quantitatively. A network based noise tolerant



















Figure 2 Performance of our method for different λ values. P-score wa
A smaller P-score (ranked higher) meant better capability to correctly rankIts performance was compared with that of the well
performing random walk approach by five-fold cross-
validation. The results confirmed the proposed method’s
robust performance with respect to data noise.
The set of known breast cancer genes (KnownSet, see
Methods) was enlarged by including genes sharing GO0.6 0.8 1.0
λ
s the average ranking of KnownSet in top 10% of the final sorted list.
known breast cancer genes.
Table 2 Ranking performance comparison
The proposed method Random walk approach
Gene Ranking Gene Ranking
RB1 89 RB1 60
CCND1 105 EP300 119
EP300 142 CCND1 227
ERBB2 171 ERBB2 326
MAP2K4 450 NTRK3 685
GATA3 463 MAP2K4 1167
BAP1 530 BAP1 1231
PBRM1 1626 GATA3 3042
ETV6 2952 PBRM1 3102
NTRK3 4030 ETV6 3355
SLC22A18 9254 SLC22A18 10971
top 10% average 279 545
all 11 test genes average 1801 2207
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http://www.biomedcentral.com/1752-0509/7/49annotations with those in the KnownSet. The enlarged
set was called the GOSet (GO enriched gene set, see
Methods), which was adopted as a noisy set of likely
breast cancer genes. The GOSet was utilized to check an
algorithm’s robustness with respect to data noise. Data
were sampled from the GOSet, and combined with the
KnowSet to generate a noisy set of training data. This
way of synthesizing noisy data set is unique in that it
doesn’t simply using random data as noise, which is
too artificial. The GOSet contains enriched but still























Figure 3 Evidence code distribution of GO annotation (for Homo sapi
electronic annotation and not curated manually. IEA counted for the majorreal life scenarios. An algorithm’s ability to retain its
performance was checked when fraction of noisy data
in the training set went up.
The proposed method did not work quite as well
as random walk approach when input data was
100% accurate, however, when noise level in input
data increased, we observed the following phenom-
ena (Figure 4).
1. Random walk approach exhibited a sharp decrease
in its performance, while our method was able to
maintain a relatively stable performance.
2. When noise increased to a large extent, the
proposed method was able to perform about twice
as well as random walk approach did.
It can thus be stated that the proposed method was
more robust with respect to noise in input data, com-
pared to the state-of-art random walk based approach.
The results also confirmed the power of data integration,
which was able to let different data sets complementing
each other [22,23].
Robustness with respect to completely random noise
GOSet tried to simulate realistic data noise. However, it
might be suspected that GOSet was biased toward the
proposed method in one way or another. To make sure
the comparison between the proposed method and the
random walk approach was not done unfairly, randomly
picked genes were added to the KnownSet (Figure 1,
Box B, see Methods), and performances of the proposedAS EXP IBA IEA IC IRD RCA IGI IDA
vidence Codes
ens). IEA means that the denoted GO annotations were inferred from
ity of GO annotations.














































Figure 4 Five-fold cross-validation performance evaluation. In cross validation, different ratios of noise data were added to input data, with
the ratio changing from 0 to 50, where 0 meant only known breast cancer genes were used as input data. Performance was evaluated in terms
of the F-score. k was a ranking threshold to judge a ranked gene as a true breast cancer gene by the proposed method. (a) k=300; (b) k=400.
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Figure 5 again showed that random walk approach
showed linear performance decline when noise increased
in the source data, while the proposed method was able to































Figure 5 Ranking comparison performance. Randomly picked genes we
method and random walk approach were then compared.Conclusions
Cancers are highly complex processes, the majority of
cancer genes are yet to be mapped. Currently available data
(known breast cancer genes) are too limited to be really
effective for cancer gene searching purpose. Broadening0.6 0.8 1.0
ise Ratio
re added to the KnownSet, and performances of the proposed
Table 3 The known breast cancer genes
Symbol NCBI_ID Symbol NCBI_ID
AKT11,2 207 RAD511 5888
AR1 367 RAD51C1 5889
ATM1 472 TP531,2 7157
BARD11 580 TSG1011 7251
BRCA11,2 672 XRCC31 7517
BRCA21,2 675 RAD54L1 8438
RAD51D1,3 5892 PPM1D1 8493
CASP81 841 RB1CC11 9821
CDH11,2 999 CHEK21,2 11200
NQO11 1728 PALB21,2 79728
ESR11 2099 BRIP11,2 83990
HMMR1 3161 BCPR1,3 8142
KRAS1 3845 BRCATA1,3 8068
NQO21 4835 SLC22A181 5002
PHB1 5245 BRCA31,3 60500
PIK3CA1,2 5290 ERBB22 2064
BAP12 8314 ETV62 2120
CCND12 595 GATA32 2625
EP3002 2033 MAP2K42 6416
PBRM12 55193 NTRK32 4916
RB12 5925
1 known breast cancer genes from OMIM database.
2 known breast cancer genes from CGC database.
3 known breast cancer genes that could not be mapped to the PPI network or
the GDSes.
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enable better use of available data to mine for new cancer
genes. Approaches that work robustly against data noise
are needed.
A novel noise tolerant breast cancer gene mining method
was presented here, which integrated a comprehensive PPI
network, gene expression data, prior knowledge of breast
cancer and GO annotations to rank potential breast
cancer genes. From each data source, a ranked list for
each candidate gene was computed, and they were then
combined into a final ranking order. Influence of data
noise was quantitatively evaluated. Random walk approach
performed better than the proposed method using 100%
accurate input data (known breast cancer genes). However,
the proposed method showed much greater noise toler-
ance. To our best knowledge, this is the first effort to
quantitatively analyse noise tolerance between different
cancer gene mining methods. The framework of the pro-
posed mining method and the quantitative way of apprais-
ing noise effects are flexible enough to be useful for other
data sources, and hopefully, lead to more discussions on
data noise issue for different computational methods in
cancer gene mining field.
Methods
Figure 1 presented a schematic view of our approach. A
comprehensive PPI network was obtained by integrating
data from different interactions databases [36] (Box A). A
set of known breast cancer genes (KnownSet) was extracted
from the OMIM and CGC databases (Box B). Candidate
genes were first ranked by three network topological attri-
butes: node degree, node betweenness and by their close-
ness to known cancer genes in the network (Box C). GO
term enrichment analyses were performed for KnownSet,
producing a GO term set enriched with breast cancer
related terms, into which a group of cancer-hallmark GO
terms were also added [37]. A set of genes which were
annotated with terms in the obtained GO set were gener-
ated, which was called the GO enriched gene set (GOSet)
(Box D). A batch of breast cancer-related expression data
was extracted from the GEO database [38] on April 7, 2011
and expression profiles in those data files were clustered
based on their similarity with each other (Box E). Expres-
sion clusters were intersected with GOSet. Overlap signifi-
cance was represented by a p-value computed with the
normal distribution. The p-value was utilized to rank genes
in expression clusters (Box F). All individual rankings from
different data sources were finally combined into a final
ranking, which represented a gene’s overall probability of
being involved in breast cancer (Box G).
Deriving known breast cancer gene set
Thirty known breast cancer genes were extracted from
the OMIM database [39] and 19 from the CGC database[40] (Table 3). For a gene to be usable, it was required to
be covered by both the PPI network and expression data
sets. With that requirement, 26 genes derived from
OMIM (OMIMSet) and 11 additional genes from CGC
(CGCSet) were obtained, this set of 37 genes was called
the KnownSet.
Ranking by PPI network
The human PPI data were derived from five sources:
HPRD [41], BioGRID [42], homoMINT [43], IntAct [44]
and a manually curated human signalling network [45].
Protein identifiers were mapped to uniform coding gene
identifiers. Official gene symbols were used as identifier.
Redundant interactions were removed, along with interac-
tions with identifiers that could not be mapped to gene
symbols (Table 1). The final PPI network was represented
by an undirected graph where nodes representing genes
and edges representing interactions. The graph contained
156,459 interactions connecting 15,494 genes.
Similarities between proteins were found to be corre-
lated with their proximity in the PPI network [46]. It was
assumed that when a gene in the PPI network exhibited
topological features similar to known breast cancer genes,
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Several papers had shown that cancer genes could be
effectively distinguished from others by their topological
attributes in the PPI network, such as node degree [47],
betweenness centrality [48] and shortest path length
[10]. The above three network topological indices were
computed and used to assess gene similarity in the PPI
network. Genes were then sorted according to values of
the topological indices.
Let G(V,E) be the PPI network, where V is the set of
genes, and E the set of interactions in the network.
For a node v∈V, degree cd(v) is the number of direct
neighbours of v in the network. Betweenness centrality
is the sum of the fraction of all-pair shortest paths that
pass through v [49]. It can be expressed as following,
cb vð Þ ¼
X
j;k∈V
σ jk vð Þ
σ jk
ð1Þ
where σ jk is the number of shortest paths from a source
j∈V to a target k∈V, and σ jk(v) is the number of those
paths passing through some node v other than j,k. If j=k,
σ jk =1, and if v∈j,k, σ jk(v)=0.
The shortest path length was defined as the average
shortest path distance from all known breast cancer
genes to node v, it can be denoted as following,
cspl vð Þ ¼ ∑ t∈G d v; tð Þ
n
ð2Þ
where G is the KnownSet, d(v,t) is the shortest path
length between node v and t. n is the number of known
breast cancer genes which can be reached by v.
The above topological attributes were computed with
the Python package networkx [50]. To facilitate later
integration step, they were transformed into rankings;
that is, each list was sorted, and a gene was assigned a
positive integer number for a specific attribute according
to that attribute’s value in the sorted list (Figure 6). In
the end, three rankings for each gene were obtained
based on its topological attributes in the network. SN(v)
was the topology-based ranking score of a gene v, which
was calculated from the three network topological attri-
butes: node degree, shortest path length and node
betweenness, SN(v) = (cd(v) + cspl(v) + cb(v))/3.
Deriving GO enriched gene set
GO provides a controlled vocabulary of terms for describing
genes and gene products [17]. GO enrichment analysis
assesses whether certain GO annotations are significantly
over represented among a set of genes [51]. The level of
enrichment can be represented by a p-value based on
specific probability distribution. The p-value is calculated
by randomly picking sets of genes from the genome andcomputing the probability of obtaining more genes with
GO terms annotated to those in the study set [52]. The
smaller the p-value, the more significant the GO term is
enriched in the gene set. For the KnownSet, we used three
tools (DAVID [53], GOstats [54], GOEAST [55]) to per-
form enrichment analyses in the BP (Biological Process)
sub-ontology. DAVID and GOEAST are online tools and
GOstats is an R package from Bioconductor [56]. The top
50 enriched terms were picked from results obtained by
each of those tools. The three enriched GO term sets from
the three tools were combined into one GO term set by
taking their union. In addition, cancer-hallmark related
GO terms are those characteristically related to cancers,
they should also be included. The set of cancer-hallmark
GO terms listed in Table 1 of [37] were added to the above
obtained GO term set, which was then remapped to a set
of corresponding genes based on human GO annotations.
Genes not covered by our PPI network were removed.
The obtained set of genes was enriched with BP terms
annotated to known breast cancer genes; they thus were
more likely to be involved in breast cancer than randomly
selected genes. This set of genes was called the GO
enriched gene set (GOSet) (Figure 7).
Ranking by gene expression and GO
All breast cancer-related gene expression datasets (key-
words: Homo sapiens & breast cancer) were download
from the GEO database [38]. Data sets with fewer than
five samples or conditions were deleted. Data sets of
normal versus cancer samples were used so those
containing recurred versus non-recurred samples were
deleted. 53 GDSes (GEO data sets) were thus obtained.
For each GDS, records with “null” information and
genes which didn’t exist in the PPI network were removed,
and if a gene had more than one expression profiles, its
expression was defined as the profile which had the largest
mean value [57], defined as:






where n is the set of expression profiles for gene i in a
GDS, m is the number of samples/conditions in one of
those profiles, and ek(j) is the corresponding expression
value of sample j.
After the above mentioned preprocessing steps, genes
in each GDS were clustered by the APCluster algorithm
according to their expression profiles. APCluster is an
algorithm based on affinity propagation which works by
considering all data points as potential cluster centers at
the same time and setting up messages of similarity
between any two data points, messages are exchanged
among data points until all clusters are determined.
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Figure 6 Ranking genes by network attributes. Genes of the PPI network were sorted according to network attributes (node degree was used
as an example here). The scores were then converted into ranking values.
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coefficient between gene expression profiles was used as
the similarity metric for APCluster. It was assumed that
genes within a cluster would have higher probability of
being involved in certain biological processes than those
across clusters.
Overlaps of expression clusters with the GOSet were
next computed. To evaluate significance of the overlaps,
the same number of genes was randomly sampled asKnown breast cancer genes
DAVID GOstats GOEAST
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Figure 7 Getting GO enriched gene set by GO enrichment
analysis. Three different tools were used to perform GO term
enrichment analyse for known breast cancer genes. Top 50 enriched
GO terms were picked from results obtained by each tool, and their
union were generated. Nine cancer-hallmark GO terms from [37]
were added into the enriched GO term set. The enriched GO term
set were re-mapped back to a set of human genes based on Homo
sapiens GO annotations, called the GO enriched gene set (GOSet).those in the cluster from GDS, and its overlap with the
GOSet was computed; the procedure was repeated 1000
times for each cluster. A p-value was then computed for
the clusters (Figure 8). Rankings were assigned to clusters
according to their p-values; that is, the lower the p-value,
the higher the position in the ranking list. Genes in the
same clusters were assigned the same ranking. A ranking
score SE(i) was thus obtained for genes in each GDS,
where i represented a specific GDS. A score SE was
assigned for each gene by computing the average of SE(i)
from all relevant GDSes.
Ranking integration
For a gene v, the ranking scores based on network
topology and expression clustering were combined into an
overall ranking as following,
S vð Þ ¼ 1−λð ÞSN vð Þ þ λSE vð Þ ð4Þ
SE(v) was the expression-based ranking score of gene
v, which was computed from breast cancer-related
gene expression data and GO annotations. λ (0≤λ≤1) is
a coefficient to weigh the contribution of topological
attributes and expression information in ranking breast
cancer genes. The average ranking of genes in the
KnownSet that sorted into top 10% was computed as the
P-score. A smaller P-score meant better performance, that
is, it was more likely to find true breast cancer genes from
the top of the sorted list. S(v) is the final ranking for a
gene v, which reflected the belief that a specific gene was a
potential breast cancer gene. The higher a gene was
ranked, the more likely it was involved in breast cancer
related processes.
Cluster i GOSet






































Figure 8 Ranking gene clusters from GEO expression profiles. For a cluster i, random samples of same size were drawn from the same GDS
and their overlaps with GOSet were computed. P-value was used to represent significance of a cluster’s overlap with GOSet. The smaller the p-











Figure 9 Computing precision and recall. A was the set of known
breast cancer genes, and B was the set of breast cancer genes
which had been predicted as breast cancer genes by the proposed
method. Precision represented ability to reject unrelated genes, and
recall represented ability to obtain true breast cancer genes.
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The steps in [13] were followed to perform random
walk. It iteratively transitions a walker from its current
node to a randomly selected neighbour. Assuming W is
the adjacency matrix of the PPI network and pt is a vector
whose i-th element holds the probability of arriving at
node i at step t. Random walk was computed by
ptþ1 ¼ 1−rð ÞWpt þ rp0 ð5Þ
where p0 is the initial probability, which is 1/37 for the 37
genes in the KnownSet and 0 for all others; r represents
the probability of remaining at the same node at the next
step. [30] showed that random walk worked robustly
against different r values, which was also confirmed by
our computation (data not shown). r was taken to be 0.7
in the current work. For details of random walk approach,
see [13].
Ranking performance comparison
OMIMSet contained 26 known breast cancer genes,
CGCSet contained additional 11. The 26 known breast
cancer genes in the OMIMSet were used as the
KnownSet. Procedure in Figure 1 was followed and the
model built, which was then used to rank the 11 known
breast cancer genes in the CGCSet. Ranking values in
italic meant those genes were ranked in the top 10% of
the final list. The row of “top 10% average” represented
average rankings of those known breast cancer genes
in CGCSet that ranked in top 10%, while “all 11 test
genes average” represented the average rankings of all 11
genes in the CGCSet (Table 2). In later computation,OMIMSet and CGCSet were combined into a KnownSet
of 37 genes.
Performance evaluation against realistic data noise
GOSet was a set of genes enriched with probable breast
cancer genes. Its quality was obviously lower than the
KnownSet, but higher than a set of random genes none-
theless. To evaluate the proposed method’s robustness
with respect to noise in real life data sources, multiples
of 37 (the number of known breast cancer genes in the
PPI network) genes were sampled from the GOSet
(ranging from 0 to 50, with 0 meaning no noise added).
Each sample was combined with the KnownSet into an
ntegrated source data. Stratified cross-validation was uti-
lized for performance comparison between the proposed
Nie and Yu BMC Systems Biology 2013, 7:49 Page 11 of 12
http://www.biomedcentral.com/1752-0509/7/49approach and the random walk method [13]. The sampled
genes were randomly partitioned into five equal subsets,
one of the five subsets was retained for testing, and the
remaining four subsets were used as training data. The
KnownSet was also randomly divided into five equal parts.
One of them was combined with one subset of the
sampled genes as testing data, the other four with the
four remaining subsets of the sample as training data.
This procedure was then repeated five times, with each
of the five subsets used once as testing data. All results
from the five folds were averaged to generate the final
result. Performance of the proposed approach and random
walk method with respect to data noise were evaluated in
terms of the F-score, which was computed from precision
and recall (Figure 9). Precision was the fraction of genes
ranked within top k in the test data that were true known
cancer genes; recall was the fraction of known breast
cancer genes ranking within top k. F-score was then the
harmonic mean of precision and recall. k was the ranking
threshold that was used to decide whether a ranked
gene was considered as a predicted positive, that is,
genes ranked higher than k were judged as breast cancer
genes. The F-score was defined as following,
F  score kð Þ ¼ 2 Precision kð Þ  Recall kð Þ
Precision kð Þ þ Recall kð Þ ð6Þ
where
Precision kð Þ ¼ A∩Bj j
Bj j ð7Þ
Recall kð Þ ¼ A∩Bj j
Aj j ð8Þ
where A is the number of genes in the KnownSet, B is
the number of genes ranked within top k.
One F-score was computed for each fold, averaging
five F-scores (for five-fold cross validation) produced the
final F-score.
Performance evaluation against completely random noise
Random genes were first sampled from the PPI network
and added to the KnownSet. Procedure in Figure 1 and
random walk computation were then performed. Figure 5
plotted the ratio of random genes to the number of
genes in KnownSet (37) and the proportion of added
random genes that ranked within top 10%.Additional file
Additional file 1: Table S1. Supplementary Table 1.
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